Idera Pharmaceuticals is a drug discovery and development company that is developing drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The Company’s proprietary drug candidates are designed to modulate specific TLRs, which are a family of immune system receptors present in immune system cells that direct the immune system to respond to potential disease threats. The Company’s pioneering DNA chemistry expertise enables us to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. The Company’s lead TLR9 agonist, IMO-2125, is currently in a Phase 1 trial for the treatment of hepatitis C virus infection. The Company has also created novel DNA-based compounds that have been shown to act as antagonists to TLRs 7 and 9 in preclinical studies. The Company is collaborating with Merck KGaA for the research, development and commercialization of our most advanced ...

Contact Information

167 Sidney Street
Cambridge, MA 02139

tel: 617-679-5500
fax: 617-679-5592


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $330M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.